Ma Lin-Lu, Li Bui-Hui, Jin Ying-Hui, Deng Tong, Ren Xue-Qun, Zeng Xian-Tao
Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Institute of Evidence-Based Medicine and Knowledge Translation, Henan University, Kaifeng, China.
Front Med (Lausanne). 2020 May 15;7:242. doi: 10.3389/fmed.2020.00242. eCollection 2020.
Recently WHO has characterized COVID-19 as a pandemic. Diagnosing the disease accurately and decreasing misdiagnoses and missed diagnoses is very important for management. Therefore, we have analyzed the seven versions of China's national guidelines to examine how the diagnostic criteria roadmap has developed and evolved, in order to share our experience worldwide. In this article, we present the developments from the first to seventh versions, involving changes of case classification, changes to "suspected case," changes in "confirmed case," changes in clinical classifications, changes in "severe case," and unchanged criteria. We have also discussed the reasons and implications for these changes and are looking forward to providing suggestions for worldwide understanding and management of this pandemic. A nucleic acid test is currently accepted as the gold standard method to confirm diagnosis. In addition, imaging examination and epidemiological history should also be considered as auxiliary diagnosis methods.
最近，世界卫生组织将新型冠状病毒肺炎（COVID-19）列为大流行病。准确诊断该疾病并减少误诊和漏诊对于疾病管理非常重要。因此，我们分析了中国国家指南的七个版本，以研究诊断标准路线图是如何发展演变的，以便在全球分享我们的经验。在本文中，我们介绍了从第一版到第七版的发展情况，包括病例分类的变化、“疑似病例”的变化、“确诊病例”的变化、临床分类的变化、“重症病例”的变化以及未改变的标准。我们还讨论了这些变化的原因和影响，并期待为全球对这一大流行病的理解和管理提供建议。目前，核酸检测被公认为确诊的金标准方法。此外，影像学检查和流行病学史也应被视为辅助诊断方法。
